Although the use of primary angioplasty in the acute myocardial infarction (AMI) setting has been shown to achieve TIMI 3 flow in the majority of patients, there are still some instances in which ...
A new meta-analysis finds no clear long-term cardiovascular benefit from beta-blockers after myocardial infarction in ...
Myocardial infarction (MI) causes millions of deaths worldwide. Though there have been advances in the survival rates following ST-elevation MI (STEMI), survivors often develop heart failure due to ...
The association between MI/PE and AECOPD severity and frequency was strongest during the first year after exacerbations occurred but still significant after 5 years. In chronic obstructive pulmonary ...
Empagliflozin stabilizes kidney function and reduces heart failure risk post-myocardial infarction, with eGFR remaining stable over 24 months. The EMPACT-MI trial confirmed empagliflozin's safety when ...
In a recent study published in Open Forum Infectious Diseases, researchers assessed myocardial infarction (MI) risk after zoster infection. MI has been described as a severe cardiovascular ...
After nonfatal myocardial infarction or stroke, initiation of a GLP-1 receptor agonist was linked to reduced risk for all-cause and CV-related mortality in patients with diabetes, researchers reported ...
Credit: Getty Images A discussion of the use of beta-blocker therapy following AMI, with Christopher Granger, MD, Gregg Fonarow, MD, and Carlin S Long, MD. Beta blockers have long been included in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results